Triglycerides and cholesterol are both carried in plasma by apolipoprotein B (ApoB)-containing lipoprotein particles. It is unknown whether lowering plasma triglyceride levels reduces the risk of cardiovascular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels.
A ll major clinical guidelines recommend treatment to lower plasma low-density lipoprotein cholesterol (LDL-C) because numerous randomized trials have demonstrated that therapies that lower LDL-C levels by reducing LDL particles through upregulation of the LDL receptor (LDLR) reduce the risk of cardiovascular events. [1] [2] [3] [4] [5] By contrast, the guidelines do not recommend treatment to lower plasma triglyceride levels because randomized trials have not provided consistent evidence that lowering plasma triglyceride levels reduces the risk of cardiovascular events. 1, 2 Several novel therapies that potently reduce triglyceride levels are currently in development. [6] [7] [8] The development of these therapies has been motivated in part by the observation that rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease; while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease. [9] [10] [11] [12] [13] However, it is unknown whether lowering plasma triglyceride levels by targeting the LPL pathway will reduce the risk of cardiovascular events. Both triglycerides and cholesterol are carried in plasma by apolipoprotein B (ApoB)-containing lipoprotein particles. Because all ApoB-containing lipoproteins, including triglyceriderich lipoprotein particles and LDL particles, have a single ApoB molecule the clinical benefit of lowering triglyceride levels can be compared with the clinical benefit of lowering LDL-C levels by estimating their effects per unit change in ApoB. Therefore, the objective of this study was to use mendelian randomization to compare the association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with the risk of cardiovascular disease per unit difference in ApoB to make inferences about the potential clinical benefit of lowering plasma triglyceride levels as compared with lowering LDL-C levels.
Methods

Study Population
The study included individual participant data from 367 641 participants enrolled in the UK Biobank study, individual participant data from 102 837 participants enrolled in 1 of 14 prospective cohort or case-control studies that reported data on cardiovascular outcomes in the US National Center for Biotechnology Information Database of Genotypes and Phenotypes program (dbGAP), and summary-level data from 184 305 participants enrolled in 1 of 48 prospective cohort, case-control, or cross-sectional studies included in the Coronary Artery Disease Genomewide Replication and Meta-Analysis plus the Coronary Artery Disease (CARDIoGRAMplusC4D) Consortium. [14] [15] [16] Participants of European descent in the UK Biobank, and all racial/ethnic groups for which cardiovascular data were reported in the dbGAP and CARDIoGRAMplusC4D Consortium studies, were included in the analysis. In each included study, race/ethnicity was self-identified using a study-specific fixedcategory questionnaire and was recorded to allow assessment of potential heterogeneity of effect estimates by ethnicity.
Contributing studies received ethical approval from their respective institutional review boards, and written informed consent was obtained from all participants. A description of the included studies and the genotyping platforms used in each study is provided in eTable 1 in the Supplement.
Genetic Instruments
The LPL genetic score was constructed by combining all variants within 100kb on either side of the LPL gene that were associated with plasma triglyceride levels at genome-wide level of significance (P <5.0×10 −8 ) as reported by the Global Lipids Genetics Consortium and that were in low linkage disequilibrium (r 2 < 0.3) with all other variants included in the score. 17, 18 The LDLR genetic score was constructed similarly by combining all variants within 100kb on either side of the LDLR gene that were associated with plasma LDL-C levels at genome-wide level of significance and that were in low linkage disequilibrium (r 2 < 0.3) with all other variants included in the score. The exposure allele for each LPL variant was defined as the allele associated with lower plasma triglyceride levels, and the exposure allele for each LDLR variant was defined as the allele associated with lower LDL-C levels. 17, 18 For each participant, an LPL genetic score was calculated by summing the number of triglyceride-lowering alleles that participants inherited at each variant included in the LPL score and an LDLR score was calculated by summing the number of LDL-C-lowering alleles that participants inherited at each variant included in the LDLR score. Participants were excluded if they had missing data for 1 or more variants included in either genetic score.
Study Outcomes
The primary clinical outcome was coronary heart disease (CHD) defined as a composite of prevalent or the first incident occurrence of myocardial infarction (MI), coronary revascularization, or coronary death. For analyses involving individual participant data, the primary clinical outcome was harmonized across all included studies. For analyses involving summarylevel data, the definition of CHD was defined by each study included in the CARDIoGRAMplusC4D consortium, which included CHD death, MI, and coronary revascularization but in some studies also included chronic stable angina or more than 50% stenosis in a major epicardial coronary artery. 16 
Study Design and Statistical Analysis
A description of the study design, analyses performed, and data used for each analysis is provided in eFigures 1-3 in the Supplement. The association of each genetic score with plasma triglycerides, LDL-C, and ApoB was evaluated using linear regression and with CHD risk using logistic regression. All regression analyses were performed separately in each of the included studies adjusting for age, sex, and the first 5 principal components of ancestry. To directly compare the clinical benefit of lower triglyceride levels due to the LPL score with lower LDL-C levels due to the LDLR genetic score, the associations of each score with risk of CHD was scaled for a common 10-mg/dL lower level of ApoB-containing lipoproteins. For individual participant data, the scaled point estimates were obtained by weighting each variant included in either genetic score by its associated change in ApoB. For summary-level data, the scaled associations were obtained by dividing the reported point estimate (and standard error) for an outcome by the reported point estimate for ApoB (measured in mg/dL). The scaled summary point estimates for all variants included in a score were then combined in a fixedeffect inverse variance-weighted meta-analysis to estimate the association between that genetic score generated using summary data and the outcome for a 10-mg/dL lower level of ApoBcontaining lipoproteins. The point estimates derived from the individual participant data and the summary data were then combined across studies in a fixed-effect inverse variance-weighted metaanalysis to produce an overall summary point estimate using a previously reported method that accounts for correlation between variants. 19 Effect modification between lowering triglyceride levels through the LPL pathway and lower LDL-C levels through the LDL receptor pathway was assessed by comparing the associations of each genetic score with the risk of CHD stratified by the other genetic score. The association of combined exposure to triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with the risk of CHD was evaluated in a 2 × 2 factorial mendelian randomization analysis. [20] [21] [22] [23] For both the stratified and factorial analyses, associations with the risk of CHD were necessarily restricted to participants with individual data and associations with changes in triglycerides, LDL-C, and ApoB were necessarily restricted to participants with individual data for whom 1 or more lipid measurements were available.
Sensitivity Analyses
To compare the potential clinical benefit of pharmacologically lowering triglyceride and LDL-C levels, the associations of the LDLR and LPL scores with the risk of CHD per unit difference in ApoB were compared with variants in the genes that encode the targets of current therapies that lower LDL-C through the LDL receptor pathway; variants in the genes that encode the targets of potential therapies that lower triglycerides through the LPL pathway; and variants in the APOB gene.
To compare the association of triglyceride and LDL-C levels with the risk of CHD per unit difference in ApoB not related to the LPL and LDLR genes, several additional genetic scores were constructed using up to 178 genetic variants associated with either triglycerides, LDL-C, or both at genome-wide significance as reported by the Global Lipids Genetics Consortium.
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To further assess the independent associations of lower triglycerides, lower LDL-C, and lower ApoB on the risk of CHD, a multivariable mendelian randomization analysis was performed using these 178 genetic variants combined with the LPL and LDLR variants. This analysis was performed using metaregression analyses in which the dependent variable was the associated log-odds for the risk of CHD, and the independent variables were the reported differences in plasma triglycerides, LDL-C, and ApoB for each variant included in the analysis, weighted by the inverse of the squared standard error for the association of each variant with CHD and forced to pass through the origin.
All analyses were performed using Stata (version 14. 
Results
Participant Characteristics
A total of 654 783 participants, including 91 129 cases of CHD, were included in the analysis (mean age, 62.7 years; 51.4% women). Individual participant data were available for 470 478 participants including 30 328 cases of CHD ( Table 1) . Summarylevel data were available for a further 184 305 participants, including 60 801 cases of CHD.
LPL and LDLR Genetic Scores
A total of 5 independently inherited variants were included in the LPL score (eTables 2 and 3 in the Supplement) and 3 independently inherited variants were included in the LDLR score (eTables 4 and 5 in the Supplement). Each exposure allele in the LPL score was associated with an inverse varianceweighted mean of 11.64-mg/dL (95% CI, 10.38-10.90;
) lower plasma triglyceride level (to convert to mmol/L, multiply by 0.0113), 0.11-mg/dL (95% CI, 0.00-0.21; P = .04) higher plasma LDL-C level (to convert to mmol/L, multiply by 0.0259, and a 1.72-mg/dL (95% CI, 1.30-2.14; P =5.5×10 −16 ) lower level of ApoB-containing lipoproteins. By contrast, each exposure allele in the LDLR score was associated with an inverse variance-weighted mean of 3.42-mg/dL (95% CI, 3.27-3.57; P =2.3×10 −464
) lower plasma LDL-C level, 0.48-mg/dL (95% CI, 0.03-0.93; P = .04) lower plasma triglyceride level, and a 2.40-mg/dL (95% CI, 2.02-2.79;
−34 ) lower level of ApoB-containing lipoproteins.
Association of Genetic Scores With Lipids and CHD per Unit Change in ApoB
For each 10-mg/dL lower level of ApoB-containing lipoproteins, the LPL score was associated with 69.9-mg/dL (95% CI, 68.1-71.6; P =7 .1×10 −1363
) lower plasma triglyceride levels and 0.7-mg/dL (95% CI, 0.03-1.4; P = .04) higher plasma LDL-C level ( Figure 1 ). By contrast, for the same 10-mg/dL lower level of ApoB-containing lipoproteins, the LDLR score was associated with 14.2-mg/dL (95% CI, 13.6-14.8; P =1.4×10 −465
) lower plasma LDL-C level and 1.9-mg/dL (95% CI, 0.1-3.9; P =.04) lower plasma triglyceride level. Despite these differences in associated lipid levels, the LPL and LDLR scores were associated with similar lower risk of CHD per 10- 
Sensitivity Analyses
In additional analyses, variants in the genes that encode the targets for several potential therapies that lower triglycerides through the LPL pathway, and variants in the genes that encode the targets of several current therapies that lower LDL-C through the LDLR pathway, were also associated with similar lower risk of CHD per unit difference in ApoB as compared with the LPL and LDLR scores and as compared with an APOB score composed of 8 independently inherited variants in the APOB gene ( Figure 2) . Furthermore, the associated lower CHD risk for each of these variants and genetic scores was log-linearly proportional to their associated absolute lower level of ApoBcontaining lipoproteins (Figure 3) .
Several additional genetic scores consisting of other variants associated with triglycerides or LDL-C at genome-wide level of significance (excluding variants in the LPL and LDLR genes)-including scores consisting of variants associated with either triglycerides or LDL-C; triglycerides but not LDL-C; LDL-C but not triglycerides; both triglycerides and LDL-C with the same direction of effect; and both triglycerides and LDL-C with opposite directions of effect-were also associated with similar lower risk of CHD per 10-mg/dL lower level of ApoBcontaining lipoproteins ( Table 2) . In multivariable mendelian randomization analyses that included both triglycerides and LDL-C in the same model, the associations between plasma triglycerides and LDL-C with the risk of CHD were independent and genome-wide significant. However, when changes in ApoB were included in these analyses, the associations between both plasma triglycerides and LDL-C with the risk of CHD became null (triglycerides: OR, 1.014 [95% CI, 0.965-1.065], P = .19; 
Discussion
In this study, triglyceride-lowering LPL variants and LDL-Clowering LDLR variants were associated with similar lower CHD risk per unit lower level of ApoB-containing lipoproteins. The associations between lower triglyceride level and lower LDL-C level with risk of CHD due to these variants appeared to be independent, additive, and proportional to the absolute change in ApoB. In addition, numerous variants in the genes that encode the targets of potential therapies that lower triglyceride levels through the LPL pathway and current therapies that lower LDL-C levels through the LDLR pathway were also associated with similar lower CHD risk per unit lower plasma ApoB levels. Furthermore, multiple genetic scores composed of other variants associated with either triglycerides, LDL-C, or both were also associated with similar lower risk of CHD per unit lower level of ApoB-containing particles, even when the associated changes in triglyceride and LDL-C levels were in opposite directions. In multivariable mendelian randomization analyses, the independent and genome-wide significant associations between triglycerides and LDL-C with the risk of CHD became null after adjusting for changes in ApoB.
The results of this study suggest that the clinical benefit of lowering triglyceride levels is similar to the clinical benefit of lowering LDL-C levels per unit change in ApoB and is proportional to the net absolute reduction in ApoB-containing lipoproteins. The results of this study therefore suggest that all ApoBcontaining lipoprotein particles, including triglyceride-rich very-low-density lipoprotein (VLDL) particles and their metabolic remnants as well as LDL particles, have approximately the same effect on the risk of cardiovascular disease per particle. As a result, the clinical benefit of lowering triglyceride levels, lowering LDL-C levels, or lowering both may be proportional to the absolute change in ApoB-containing lipoproteins, regardless of the observed changes in plasma triglycerides or LDL-C.
The results of this study are consistent with the current understanding of the biology of lipids and atherosclerosis. Both triglycerides and cholesterol are carried in plasma by ApoBcontaining lipoprotein particles. These particles are secreted by the liver as VLDL particles, which principally contain triglycerides, some cholesterol, and 1 molecule of ApoB. Lipoprotein lipase removes most of the triglycerides from these particles to convert the triglyceride-rich VLDL particles into triglyceridedepleted cholesterol-carrying LDL particles, which are then removed from plasma by hepatic LDL receptors. All ApoBcontaining lipoproteins less than 70 nm in diameter, including triglyceride-rich VLDL remnants and LDL particles, freely flux across the endothelial barrier where they can become retained in the artery wall. 24 The cholesterol, and perhaps triglyceride, content of the ApoB particles retained in the artery wall provokes an inflammatory response that leads to the initiation and progression of atherosclerotic plaque. 25 The results of this study suggest that the effect of ApoB-containing particles on the risk of atherosclerotic cardiovascular disease appears to be determined largely by the concentration of circulating ApoB particles, which in turn determines the number of particles that become retained in the artery wall, regardless of whether those particles principally contain cholesterol or triglycerides. The present findings and interpretations based on mendelian randomization confirm and extend the initial findings and interpretations in 1980 of Sniderman and colleagues, 26 which were based on cross-sectional coronary angiographic studies. The results of this study are also consistent with prior mendelian randomization studies demonstrating that triglyceriderich ApoB-containing remnant particles appear to be causally The figure shows the associations with triglycerides, LDL-C, and risk of CHD for the same 10-mg/dL lower ApoB-containing lipoprotein concentration for variants in the LPL and LDLR scores as compared with variants in the genes that encode the targets of current therapies that lower LDL-C through the LDL receptor pathway; variants in the genes that encode the targets of potential therapies that lower triglycerides through the LPL pathway; and variants in the APOB gene. The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles. Furthermore, the results of this study are consistent with a recent mendelian randomization study that demonstrated that the causal effect of LDL particles on the risk of cardiovascular disease appears to be determined by the concentration of circulating LDL particles as measured by ApoB rather than by the mass of cholesterol carried by those particles as measured by LDL-C. 23 The results of the current study confirm and extend those findings by suggesting that the causal effect of all ApoB-containing lipoprotein particles on the risk of cardiovascular disease appears to be determined by the circulating concentration of those particles rather than by the mass of cholesterol or triglyceride that they carry.
The results of this study may also help to explain why prior randomized trials evaluating fibrates, which lower plasma triglyceride levels at least partially through the LPL pathway, have failed to consistently demonstrate that lowering triglyceride levels reduces the risk of cardiovascular events. [29] [30] [31] [32] [33] The concentration of triglyceride-rich lipoproteins can be estimated by dividing plasma triglyceride concentration by 5 (on the mg/dL scale). Therefore, if all ApoB-containing particles have approximately the same atherogenic effect as suggested by this study, then to reduce the risk of cardiovascular events by 20% as can be achieved by lowering LDL-C levels by 40 mg/dL, 3, 4 triglyceride levels must be reduced by 5-fold this quantity, or approximately 200 mg/dL, to achieve the same corresponding reduction in ApoB-containing lipoproteins. However, the mean reduction in plasma triglyceride concentration in the fibrate trials was only 20 mg/dL to 50 mg/dL, a fraction of what would be needed to significantly reduce the risk of major vascular events within a shortterm trial. Therefore, the results of the fibrate trials appear to be explained by the modest reductions in triglyceride level and therefore the modest corresponding reductions in ApoBcontaining lipoproteins observed in these studies. Future randomized trials evaluating novel therapies that lower plasma triglyceride levels should be designed based on the net absolute reductions in ApoB-containing lipoproteins that can be achieved with those therapies, rather than on the corresponding therapeutic changes in triglycerides or LDL-C, particularly for therapies that alter plasma concentrations of both triglycerides and LDL-C either in the same or competing directions.
Limitations
This study has several limitations. First, this study compared triglyceride-and LDL-C-lowering genetic variants not lipidlowering therapies. Second, genetic variants reflect the effect of lifelong changes in ApoB-containing lipoproteins on the risk of cardiovascular disease, which appear to be cumulative over time. 5, 34 As a result, the lower risk associated with lower triglycerides, LDL-C, and ApoB reported in this study is much larger than what have been reported for lipid-lowering therapies in randomized trials. However, having first established that the association between lifetime exposure to lower triglycerides and LDL-C on the risk of cardiovascular disease is approximately the same per unit lower level of ApoB-containing particles, it is reasonable to Abbreviations: ApoB, apolipoprotein B; CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol.
a Data presented are derived from a multivariable meta-regression analysis of 186 genetic variants, including the 5 variants included in the LPL score, 3 variants included in the LDLR score, and 178 variants associated with either triglycerides, LDL-C, or both at genome-wide significance as reported by the Global Lipids Genetics Consortium. Effect sizes for the associated risk of CHD are reported per 10-mg/dL lower ApoB concentration, per 10-mg/dL lower LDL-C level, or per 50-mg/dL lower triglyceride level (because dividing triglyceride concentration by 5 estimates the cholesterol content carried by triglyceride-rich ApoB-containing lipoproteins as estimated by the Friedewald formula). In these analyses, the dependent variable was the effect estimate for risk of CHD in all 654 783 participants included in the study for each variant and the independent variables were the effect estimates for the associated changes in plasma triglycerides, LDL-C, and ApoB, measured in up to 305 699 participants in Global Lipids Genetics Consortium for each variant. The analysis was weighted by the inverse squared standard error of the associated risk of CHD for each variant and forced to pass through the origin. For example, in multivariable mendelian randomization analyses involving these 186 genetic variants, both triglycerides (odds ratio [OR], 0.876 per 50-mg/dL lower triglycerides) and LDL-C (OR, 0.862 per 10-mg/dL lower LDL-C) were independently associated with a lower risk of CHD at genome-wide level of significance. By contrast, when ApoB was included in the multivariable mendelian randomization analyses, the associations with CHD for both triglycerides (OR, 1.014 per 50-mg/dL lower triglycerides) and LDL-C (OR, 1.010 per 10-mg/dL lower LDL-C) became null, but the association per 10-mg/dL lower ApoB remained unchanged (OR, 0.761 per 10-mg/dL lower ApoB). The unadjusted associations with triglycerides, LDL-C, ApoB, and CHD for each variant included in the analysis are provided in eTable 7 in the Supplement. Additional multivariable meta-regression analyses for various combinations of these variants is provided in eTable 8 in the Supplement. then anticipate that short-term pharmacologic reductions in plasma triglyceride and LDL-C levels will be associated with the same lower risk of cardiovascular events per unit change in ApoB. 21 Third, this study specifically estimates the clinical benefit of the lipid-lowering effect of therapies that reduce plasma triglycerides, LDL-C, or both, but not the other potential pleiotropic effects that a therapy may have on the risk of cardiovascular disease. Indeed, the reported reductions in cardiovascular events in the JELIS and REDUCE-IT trials were far greater than what would have been expected from the modest observed changes in plasma lipid levels, thus suggesting that the observed clinical benefit of the omega-3 fatty acid eicosapentaenoic acid may be largely due to its non-lipid-related effects.
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Conclusions
Triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants were associated with similar lower risk of CHD per unit difference in ApoB. Therefore, the clinical benefit of lowering triglyceride and LDL-C levels may be proportional to the absolute change in ApoB. were combined to create an LPL genetic score, and all approximately independently inherited variants in the LDLR gene that are conditionally independently associated with plasma LDL C levels at genome wide level of statistical significance were combined to create to create an LDLR genetic score. These genetic scores are instruments of randomization that reflect the combined effect of the variants included in the respective score on plasma lipid and lipoprotein levels. As a result, each score has a much larger effect on plasma lipid and lipoprotein levels than any individual variant included in the respective score.
To select variants for inclusion in the LPL genetic score, the following protocol was used. First, the association of each variant within a 100 KB window of the LPL gene was tested in a linear regression model where the dependent variable was triglycerides (the major lipid effect of lipoprotein lipase) and the independent variables were age, sex, study sample, and 5 principal components of ancestry to select the variant that was most strongly associated with plasma triglyceride levels in up to 54,837 participants enrolled in one of the dbGAP studies who were free of cardiovascular disease at baseline and for whom one or more measurements of plasma lipids and lipoproteins was available. Next, we iteratively tested the association of each remaining variant in the same linear model where the dependent variable was triglyceride level and the independent variables were age, sex, study sample, 5 principal components of ancestry, plus all variants selected in a previous step of the algorithm. The variant that was associated with triglycerides in this conditional analysis with the lowest p value below a threshold of 5 × 10 8 was added to the set of selected variants. Once a variant was included in the analysis, all other variants that were correlated with the selected variant at r 2 > 0.3 were removed from the set of candidate variants.
1,2
We then iteratively repeated this process until all variants were either selected, removed due to linkage disequilibrium with a selected variant, or were not strongly associated (p < 5 × 10 We defined the exposure allele for each variant included in the LPL score as the allele associated with lower plasma triglyceride levels; and the exposure allele for each variant included in the LDLR score as the allele associated with lower plasma LDL C levels as reported by the Global Lipid Genetics Consortium (GLGC). 3, 4 Both triglycerides and cholesterol are carried in plasma by apoB containing lipoproteins, which can become retained in the artery wall leading to the initiation and progression of atherosclerotic plaque.
Furthermore, all apolipoprotein B containing lipoproteins synthesized by the liver (including triglyceride rich VLDL particles, VLDL remnant particles, and LDL particles) contain a single apoB 100 molecule the association of the LPL and LDLR genetic scores on lipids, lipoprotein levels and the risk of CHD can be compared directly per apoB containing lipoprotein particle by comparing the associations of these genetic scores per unit change in plasma apoB levels. Thus, to directly compare the effect of the LPL and LDLR scores, each exposure allele included in either genetic score was weighted by its effect on apoB.
To measure the association of each variant included in the LPL score on apoB levels conditional on the presence of all other variants included in the LPL score, the association of each variant with apoB was measured in a linear regression model where the dependent variable was plasma apoB level and the independent variables were age, sex, study sample, the first 5 principal components of ancestry, and all variants included in the LPL score selected using the algorithm described above. Similarly, to measure the association of each variant included in the LDLR score on apoB levels conditional on the presence of all other variants included in the LDLR score, the association of each variant with apoB was measured in a linear regression model where the dependent variable was plasma apoB level and the independent variables were age, sex, study sample, the first 5 principal components of ancestry, and all variants included in the LDLR score selected using the algorithm described above. The conditional apoB analyses were performed in an independent external sample including up to 63,890 participants with available measurements of plasma apoB levels from the MAGNETIC NMR GWAS consortium and INTERVAL Bioresource studies. 5, 6 All studies used the same NMR platform to measure the plasma concentration of apoB using the same protocol.
To calculate the LPL genetic score for each participant weighted by apoB, the number of exposure alleles that a participant inherited at each variant included in the LPL score was multiplied by the conditional effect of that variant on plasma apoB concentration measured in mg/dL. These values were then © 2019 American Medical Association. All rights reserved.
summed to create a weighted LPL genetic score for each participant. Similarly, the LDLR genetic score for each participant weighted by apoB was calculated by multiplying the number of exposure alleles that a participant inherited at each variant included in the LDLR score by the conditional effect of that variant on plasma apoB concentration measured in mg/dL, and then summed.
II. Allocation into exposure groups for stratified and 2x2 factorial Mendelian randomization analysis
Because all variants included in either genetic score are inherited approximately randomly at the time of conception in a process sometimes referred to as Mendelian randomization, 7 and because each variant
is inherited approximately independently of the other polymorphisms included in the score by virtue of low linkage disequilibrium as defined by the construction of the score, the number of exposure alleles that a person inherits in either score should also be random.
To perform the stratified analyses, each genetic score was first dichotomized as having a value above or below the median score for participants in the population under study. Because the number of exposure alleles that a person inherits in either score should be random, dichotomizing the genetic score as above and below the median should therefore randomly allocate participants under study into two approximately equal sized groups. The association between each score and changes in plasma triglyceride, plasma LDL C levels, and the risk of CHD was then measured separately among participants with scores less than or equal to the median and greater than the median value for the other score., and effect estimates were compared using a z statistic to assess for heterogeneity of effect estimates.
To conduct the 2x2 factorial analyses, study participants were first randomly allocated into two groups based on whether their LDLR genetic score was above or below the median value. Participants in either of these two groups were then randomly allocated into two further groups based on whether their LPL compared to the reference group), and a group with both scores above the median (i.e. a group with lower LDL C but not lower TG compared to the reference group). 8, 9 The success of the naturally random allocation scheme was assessed by comparing baseline characteristics among persons in each group being compared. Continuous variables were compared using a t test, dichotomous (and ordinal) variables were compared using a chi square test, and non normally distributed variables were compared using non parametric rank tests or empirical resampling.
III. Harmonized definition of cardiovascular outcome events
The primary outcome for the study was CHD, defined as a composite of the first occurrence of non fatal MI, coronary revascularization or coronary death. Both prevalent and incident cases of MI were included in the primary composite to meet the definition of "first occurrence" (understanding that all coronary deaths during follow up were necessarily incident events) in the cohort studies. Therefore, the primary cardiovascular outcome is a composite of prevalent MI or prevalent coronary revascularization;
or the first occurrence of incident MI, incident coronary revascularization or coronary death.
For participants enrolled in the dbGAP studies, the definition of all cardiovascular related outcome was first harmonized as previously described. 10 18 Individual level data was then coded for each study participant as necessary to satisfy the harmonized variable definitions to the extent possible, as described below.
In general, and where possible, only the outcomes of coronary heart disease death (as adjudicated by the individual studies); "definite" myocardial infarction (excluding "silent MI", "possible MI", "probable MI", "ECG detected prior MI" and "resuscitated cardiac arrest"); and coronary revascularization (defined as "angioplasty", "percutaneous coronary intervention" or "coronary artery bypass grafting") were included. New reconciled study outcome variables were created in each data set using the definitions described above.
We did not recode the "case" definition for the case control studies. In the six (6) Myocardial Infarction Genetics (MIGEN) Consortium case control studies, all "cases" were MI. 18 Therefore, because MI is a component of the primary outcome, these "cases" were included in the primary composite outcome.
© 2019 American Medical Association. All rights reserved.
In the Wellcome Trust Case Control Consortium (WTCCC) study, "cases" had a history of either myocardial infarction or coronary revascularization before the age of 66 years, and a family history of coronary artery disease. 19 Of the 1,926 WTCCC "cases", 1,377 had MI (71.5%) and the remaining 549 had coronary revascularization (202 PCI; 347 CABG) as the case ascertainment event. Therefore all "cases" in the WTCCC met the criteria for a primary composite outcome event and were included in the analyses.
In the UK Biobank, data for each of components of the primary composite outcome was available for all participants enrolled in the study. 19 These outcomes included nonfatal MI [UK Biobank's algorithmically The definition of CHD in studies that provided summary level data was defined by the individual studies included in the CARDIoGRAMplusC4D consortium (www.CARDIOGRAMPLUSC4D.org).
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Case status was defined in these studies by an inclusive CHD diagnosis (e.g. MI, acute coronary syndrome, chronic stable angina, PCI or coronary stenosis >50%). Approximately 70% of total number of CHD cases in the CARDIoGRAMplusC4D consortium studies were defined by a reported history of MI.
IV. Analytic methods
In studies with individual participant data, the association between each weighted genetic score and plasma lipid levels was evaluated using linear regression, and the association with CHD was evaluated using logistic regression (for combined prevalent and incident outcomes) or proportional hazards models (for incident events). All analyses were adjusted for age, gender and the first five principal components of ancestry.
In the main analysis, the associations for each score were adjusted for a standardized decrement of 10 mg/dl lower plasma apoB concentration. In the stratified analyses, the associations for either genetic score was calculated separately among participants with values of the other score equal to or below the median value for that score; and among participants with values of the other score above the median.
In the 2x2 factorial analysis, the group with both the LPL and LDLR scores below the median was used as the reference group. The associations with changes in lipid levels and the risk of CHD for each group was compared to the reference group.
To calculate association of the LPL and LDLR genetic scores on plasma lipid levels scaled for a given change in apoB containing lipoproteins in studies with summary level data, the reported association was looked up between each variant included in the LPL and LDLR score, respectively, with plasma triglycerides and LDL C in up to 316,391 participants as reported by the Global Lipids Genetic Consortium (GLGC). 2, 3 The reported lipid effect size (and the corresponding standard error) was then adjusted by the conditional effect of that variant on apoB (measured in mg/dl) using the usual ratio of effect estimates method (i.e. dividing the effect of each variant on plasma triglycerides and LDL C by the effect of that allele on apoB). The adjusted effect estimates for each LPL variant was then combined in a fixed effect inverse variance weighted meta analysis to measure the association between the LPL genetic score and plasma lipid levels per unit lower apoB. Similarly, the adjusted effect estimates for each LDLR variant was combined in a fixed effect inverse variance weighted meta analysis to measure the association between the LDLR genetic score and plasma lipid levels per unit lower apoB.
To calculate association of the LPL and LDLR genetic scores on the risk of CHD scaled for a given change in apoB containing lipoproteins in studies with summary level data, the association was looked up between each variant included in the LPL and LDLR score, respectively, with the risk of CHD as reported by the CARDIoGRAMplusC4D consortium (www.CARDIOGRAMPLUSC4D.org). 20 The reported CHD effect sizes in natural log units (and the corresponding standard error) were then adjusted by the effect of each variant on apoB (measured in mg/dl) ) using the usual ratio of effect estimates method (i.e. dividing the effect of each variant on the risk of CHD in natural log units by the effect of that allele on apoB). The adjusted effect estimates for the LPL variants were then combined in a fixed effect inverse variance weighted meta analysis to measure the association between the LPL genetic score and the risk of CHD per unit lower apoB; and the adjusted effect estimates for the LDLR variants were combined in a fixed effects inverse variance weighted meta analysis to measure the association between the LDLR genetic score and the risk of CHD per unit lower apoB.
All analyses were conducted in separately in each study using individual participant data (or each consortium using summary level data) and then combined across all studies to produce overall summary estimates of effect using a generalized linear regression model that takes into account partial correlation due to low linkage disequilibrium between variants included in either score. 21 If variants were uncorrelated, this method would be equivalent to combining the variant specific causal estimates in an inverse variance weighted meta analysis (or combining the variants into a single genetic score variable and calculating the Mendelian randomization ratio estimate using this score).
To combine study specific effect estimates across studies, a matrix of genetic correlations between variants included in each score, respectively, was estimated in participants not having a previous CHD event at baseline only. The regression model was:
where is the Mendelian randomization causal estimate, is a vector of the genetic associations (beta coefficients) with the risk factor, is a vector of the genetic associations with the outcome, and the weighting matrix has terms , where is the standard error of the genetic association with the outcome for the jth variant, and is the correlation between the j 1 th and j 2 th variants. The causal estimate from this weighted generalized linear regression is , and the standard error is , where T is a matrix transpose, and is the maximum of the residual standard error from the regression model and 1. This is equivalent to assuming a multiplicative random effects model on the variant specific causal effect estimates. By fixing to be no lower than 1, we ensure that the random effects analysis is no more precise than a fixed effect analysis would be. This method has been described previously and was implemented using the Mendelian Randomization package in R (available for download at https://cran.r project.org/web/packages/MendelianRandomization/). When run as a fixed effect analysis, it is equivalent to the commonly used two stage least squares method that requires individual level data.
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The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Data are from genetic variants associated with either triglycerides, LDL C or both at genome wide significance as reported by the updated Global Lipids Genetics Consortium and listed in eTable 6. Effect sizes for the associated risk of coronary heart disease are per 10 mg/dl decrease in apoB; 10 mg/dl decrease in LDL C, or a 50 mg/dl decrease in triglycerides (because dividing triglyceride concentration by 5 estimates the cholesterol content carried by triglyceride rich apoB containing lipoproteins as estimated by the Friedewald formula). The results are derived from a multivariable meta regression analysis where the dependent variable is the effect estimate for risk of coronary heart disease, and the independent variables are the effect estimates for the associated changes in plasma triglycerides, LDL C and apoB, for each variant. The analysis was weighted by the inverse squared standard error of the associated risk of CHD for each variant; and forced to pass through the origin. 
